Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
Public ClinicalTrials.gov record NCT04026178. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized Lipodystrophy
Study identification
- NCT ID
- NCT04026178
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 11 participants
Conditions and interventions
Conditions
Interventions
- Metreleptin Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2018
- Primary completion
- Oct 30, 2024
- Completion
- Oct 30, 2024
- Last update posted
- Nov 25, 2025
2018 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ. Alabama-Birmingham | Birmingham | Alabama | 35294 | — |
| Ochsner Clinic | New Orleans | Louisiana | 70121 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Endocrinology Research Associates | Columbus | Ohio | 43201 | — |
| Ohio State University | Columbus | Ohio | 43203 | — |
| Childrens Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| University Texas Southwestern INT | Dallas | Texas | 75390 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04026178, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04026178 live on ClinicalTrials.gov.